ASX Life Sciences stocks: Mr. Biotech thinks that 2023 could be a very good year to buy them
Marc Kennis, May 1, 2023
ASX Life Sciences stocks are back, baby!
ASX Life Science stocks have suffered heavily in 2022 due to investors shifting out of risk assets, resulting in a bear market for biotech and medical devices. However, our own Mr. Biotech, Stuart Roberts, believes that now is a good time to buy ASX Life Science stocks, as many high-quality businesses are being overlooked due to poor sentiment.
The bear market has wiped out stocks that were overvalued due to COVID-19 enthusiasm and attracted tourist investors. Stuart sees this as an opportunity to invest in undervalued companies with potential for disruption, although they are currently trading below net asset backing and below cash.
He says stocks to look at include Race Oncology (ASX: RAC), Paradigm Biopharmaceuticals (ASX: PAR), Prescient Therapeutics (ASX: PTX).
Stuart Roberts on AusBiz talking ASX Life Sciences stocks
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
There’s no credit card needed – the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY26
Recent Posts
AMA Group Insider Buys 2 Million Shares at 10 Cents: Distressed Opportunity or Value Trap?
AMA Group (ASX: AMA) director Brian Austin just bought another 2 million shares at 10 cents apiece, his third substantial…
Why Matt Tripp Is Doubling Down on Betr After Losing the $400M PointsBet Battle
Betr Entertainment (ASX: BBT) lost the brutal battle for PointsBet in September 2025, with Japan’s MIXI securing 51.86% control through…
Aristocrat Leisure Falls Despite Strong FY25 Results: Is the Market Wrong About This Gaming Giant?
Aristocrat Leisure (ASX: ALL) shares fell 3.4% to $62.10 on results day and have since drifted to around $59, despite…